Retrospective analysis of the success and safety of Gold Micro Shunt Implantation in glaucoma by unknown
Hueber et al. BMC Ophthalmology 2013, 13:35
http://www.biomedcentral.com/1471-2415/13/35RESEARCH ARTICLE Open AccessRetrospective analysis of the success and safety
of Gold Micro Shunt Implantation in glaucoma
Arno Hueber1*, Sigrid Roters1, Jens F Jordan2 and Walter Konen1Abstract
Background: To evaluate the success rate and adverse effects of Gold Micro Shunt Plus (GMS+) implantation into
the supraciliary space.
Methods: This retrospective study included 31 eyes of 31 patients diagnosed with severe glaucoma and
uncontrolled intraocular pressure (IOP) with implantation of a GMS+ by means of a full-thickness scleral flap. The
main outcome measures were surgical failure or success, based on the intraocular pressure and adverse effects.
Clinical examination data are reported up to 4 years postoperatively.
Results: Thirty eyes (97%) met one of our criteria for failure. Within a mean of 7.3 ± 7.7 months another surgery was
performed because of elevated IOP in 24 of 31 eyes (77%) and because of adverse effects in 2 (6%). The remaining
4 eyes, that met one of our criteria for failure, had an IOP reduction of less than 20% with comparable medication.
Six GMS+’s were explanted; because of IOP elevation, 2; rubeosis iridis, 2; and low grade inflammation, 2.
Conclusions: GMS+ implantation is not an effective method to control IOP in patients with glaucoma, when using
our surgical technique. The reason for the found signs of chronic low grade inflammation or rubeosis iridis in 4 eyes
(13%) remains unknown and has to be further investigated.
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A recent, alternative approach to treating glaucoma with
filtration procedures, such as trabeculectomy, is the drai-
nage of aqueous humor from the anterior chamber (AC)
to the suprachoroidal space. This approach avoids the con-
junctiva, which is known to be responsible for the failure
of trabeculectomies. Another advantage to this shunt route
is that the pressure in the suprachoroidal space serves as a
natural counter pressure to prevent severe postoperative
hypotony. Emi et al. [1] found a drop in hydrostatic pres-
sure from the anterior chamber to the suprachoroidal
space up to -3.7 ± 0.4 mmHg that increased with experi-
mentally raised intraocular pressure. This negative pressure
in the suprachoroidal space provides the rational for a
shunt from the AC to the suprachoroidal space to lower
the intraocular pressure (IOP). Aqueous filtration across
the sclera may be another possible outflow pathway [2].* Correspondence: arno.hueber@uni-koeln.de
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reproduction in any medium, provided the orWe reported our encouraging experience with a sili-
cone shunt which connected the anterior chamber to
the suprachoroidal space [3]. We then exploited the ad-
vantages of this novel shunt route, but replaced silicone
with gold as the shunt material, seeking a more stable
and safe IOP reduction. Therefore we evaluated this re-
cent device for suprachoroidal drainage, the Gold Micro
Shunt Plus (GMS+).Methods
This was a retrospective study of patients with uncon-
trolled intraocular pressure who underwent GMS+
implantation from February 2006 to June 2008 at the
Department of Ophthalmology, University of Cologne,
Germany. Our local Ethic Board was notified and de-
termined that the board’s approval was not necessary
in a retrospective study.Shunt design
The GMS+ (SOLX ltd, Waltham, Massachusetts) is a
recently developed device for suprachoroidal drainage.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Clinical photographs of the GMS+. (A, upper) GMS+
gonioscopically one month after surgery. (B, middle) GMS+ one
year after surgery with conjunctival hyperemia, deep and superficial
corneal neovascularization and rubeosis iridis in a patient with
POAG. (C, lower) After explanation of the GMS+, the color of the
choroid changed from dark red-blue to gray.
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biocompatible, 99.95% 24-carat gold. The GMS+ is a thin
plate which measures 5.2 mm in length, 3.2 mm in width
and 68 μm in height. Nine or nineteen micro channels in
the GMS+ have a height of 40 μm and a width of 50 μm.
We could not determine which of the GMS+ shunts used
9 or 19 microchannels because the design of the GMS+
changed and the manufacture did not provide us lot-
specific design information.
Data collection
Preoperative data collected from the patient records in-
cluded age at the time of surgery, IOP on the day prior
to GMS+ implantation, prior ocular surgical procedures,
specific glaucoma diagnosis and other ocular history,
IOP lowering medications, and Cup-disc ratio.
Postoperative data were collected from the patient re-
cords from all consecutive visits. Collected data included
IOP measurements, IOP lowering medications, surgical
complications, additional surgical procedures performed,
and follow-up time. Clinical examination data were
reported up to 4 years postoperatively.
Surgical technique
Patients were operated on under general anesthesia or local
anesthesia using a sub-Tenon injection. A fornix-based
conjunctival flap was fashioned, followed by cautery of
episcleral vessels. In 4 of 31 eyes mitomycin C (0.2 mg/ml)
was applied to the sclera by means of a sponge for 2 mi-
nutes. Then the sclera was rinsed extensively with balanced
salt solution. A 3 × 3 mm triangular, full-thickness, scleral
flap was created 2 mm posterior to the limbus to expose
the supraciliary space. The AC was entered at a plane of
90% scleral thickness using a 2.8 mm knife. Dissection into
the suprachoroidal space posteriorly for 2 to 3 mm was
done using hypromellose injection (AT.Viscose®) from Acri.
Tec (Hennigsdorf, Germany). Next, the anterior segment of
the GMS+ was introduced into the AC and the posterior
segment was placed into the suprachoroidal space, ensuring
that the implant was placed so that 1.0 to 1.5 mm of the
GMS+ were visible in the AC. Two 10–0 nylon sutures
were used to close the scleral wound securely. The con-
junctiva was closed with two 8–0 vicryl sutures. All eyes
were treated with Dexamethasone-Gentamycin eye drops 4
times daily for at least 2 weeks postoperatively. All patients
underwent a GMS+ implantation by one surgeon (WK).
After surgery the correct position of the GMS+ was con-
firmed by slit lamp examination in all cases (Figure 1A) and
in 12 eyes (39%) the position was also confirmed by
50 Mhz ultrasound (Zeiss-Humphrey, System Model 840).
Data evaluation
The primary outcome measure was surgical success, de-
fined as IOP less than 21 mmHg and greater than 5 mmHg
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at least 6 months after GMS+ implantation. The post-
operative use of IOP-lowering medications was evalu-
ated, but was not considered in matters of surgical
success. Criteria for failure were: 1) IOP outside the
success range on one visit at least 6 months after GMS+
implantation, 2) serious complications at any time or
3) need for additional glaucoma surgery (except GMS+
repositioning) at any time. Serious complications included
retinal detachment, endophthalmitis, suprachoroidal
hemorrhage, low grade inflammation and newly devel-
oped rubeosis iridis. Intraoperative and postoperative
complications were also recorded. For evaluation of the
IOP lowering therapy, the number of different active
ingredients were summed to a maximal of six. The 6 dif-
ferent active ingredients were beta blocker eye drops,
sympathomimetic eye drops, parasympathomimetic eye
drops, carbonic anhydrase inhibitor eye drops, prosta-
glandin analogue eye drops and carbonic anhydrase in-
hibitor tablets.
Patients were excluded from the study, if there was no
failure but the follow-up time after surgery was less than
6 months. Analysis was performed with one eye per pa-
tient (n = 31 patients), including only the first eye that
underwent GMS+ implantation. No patient received
GMS+ implantation in both eyes simultaneously. The
length of follow-up was defined as the time between
the surgery and the next intervention (except GMS+
repositioning) or if there was no other surgery the last
post-operative visit.
Results
We identified 43 eyes of 38 patients, that received a GMS+
between February 2006 and June 2008. Five eyes were ex-
cluded, because of previous GMS+ implantation in the
other eye. Another 7 eyes were excluded from the study,
because the follow-up time after implantation, without
additional glaucoma surgery, was less than 6 months. We
included 31 eyes of 31 patients who were female, 15, and
male, 16, with an age range from 28 to 82 years, mean age
60.0 ± 15.3 years. They were diagnosed with uncontrolled
IOP and with the following types of glaucoma; primary
open angle glaucoma (POAG), 17; pseudoexfoliation glau-
coma (PEX), 5; secondary glaucoma (Sec), 4; pseudophakic
closed-angle glaucoma (CAG), 3; and pigmentary glau-
coma (Pigment), 2. In the group of secondary glaucoma,
there were two patients with a known uveitis, one with a
neovascular glaucoma and one with a history of silicone oil
retinal surgery. Eighteen eyes were phakic and 13 eyes were
pseudophakic. In 16 eyes (52%), the GMS+ was the first
incisional glaucoma procedure. The remaining 15 eyes
had unsuccessful prior procedures, as shown in Table 1.
Before GMS+ implantation the cup-disc ratio, assessed by
the surgeon, ranged from 0.4 to 1.0 (mean 0.88 ± 0.16) andthe IOP ranged from 12 to 57 mmHg (mean 26.58 ±
10.14 mmHg). The sum of the number of different active
ingredients in IOP lowering therapy ranged from 0 to 5
(mean 2.13 ± 1.61). The characteristics of the patients are
summarized in Table 1.
On the first day after GMS+ implantation the IOP
ranged from 0 to 24 mmHg (mean 6.1 ± 5.1 mmHg). In
three eyes the GMS+ was barely visible in the AC; so 3
to 10 days after initial implantation the position was re-
vised to move the GMS+ 1.0 to 1.5 mm into the AC.
Altogether 30 of the GMS+ implanted 31 eyes met at
least one of our criteria for failure; several met more than
one criterion, as shown in Table 1. Within a mean of 7.3 ±
7.7 months another surgery was performed because of
elevated IOP in 24 of 31 eyes (77%) (trabeculectomy
with mitomycin C in 19 eyes, Baerveldt implantation in
3 eyes and one each of cryotherapy, and phacoemulsi-
fication with GMS+ explantation). Another surgery, GMS+
explantation, was required in 2 (6%) patients due to
rubeosis iridis and low grade inflammation, without ele-
vated IOP. The remaining 4 eyes, that met one of our cri-
teria for failure, had an IOP reduction of less than 20%
with comparable medication, as shown in Table 1. The sur-
vival curve is shown in Figure 2. The 1-year failure rate
was 71% and the 2-year failure rate was 90%.
One eye had an IOP after the GMS+ implantation
of 14 mmHg after 46.1 months of follow up and was
considered a success. This patient had epithelial and
stromal corneal edema and corneal neovascularization be-
fore GMS+ implantation.
For all 31 patients, the mean IOP at the end of the
study was 27.19 ± 10.44 mmHg. The sum of the different
active ingredients in IOP lowering therapy at the end of
the study was 1.55 ± 1.39.
As shown in Table 1, six GMS+ were explanted. In two
eyes with POAG the GMS+ was explanted because of el-
evated IOP without visible signs of chronic inflammation
and combined with a trabeculectomy with mitomycin C.
In one eye with POAG, newly diagnosed rubeosis iridis
and a deep vascularisation surrounding the GMS+
(without elevated IOP) were the cause for the explant-
ation of the GMS+ (Figure 1B). In one eye with second-
ary glaucoma due to uveitis, the GMS+ explantation was
combined with a trabeculectomy with mitomycin C and
indicated due to elevated IOP and newly diagnosed
rubeosis iridis surrounding the GMS+. In one eye with
POAG the GMS+ was explanted because of recurring
pain and recurring mild intraocular inflammation with-
out elevated IOP. In one eye with pseudoexfoliation glau-
coma the GMS+ was explanted because of elevated IOP
and newly diagnosed keratic precipitates. During im-
plantation of the GMS+ the choroid had a dark red-blue
color, but during explantation of the GMS+, the choroid
was gray (Figure 1C).
Table 1 Summarized characteristics of the patients
Agea Glaucoma Previous interventionsb Cup-disc ratio Baseline IOPc End IOPd Follow up months Next intervention Outcomee
70 Sec P-T1 0.95 57 (4) 24 (0) 5.8 T F(3)
70 POAG none 0.80 34 (3) 44 (1) 8.9 T F(1,3)
70 PEX P 1.00 40 (3) 39 (3) 1.4 T F(3)
60 POAG none 0.95 16 (3) 21 (4) 2.2 T F(3)
60 POAG none 1.00 34 (0) 32 (3) 5.8 T F(3)
80 POAG P 0.85 18 (1) 17 (3) 5.0 T F(3)
60 POAG none 1.00 34 (0) 30 (3) 5.3 T F(3)
70 POAG P 0.80 17 (0) 17 (3) 7.9 T F(1,3)
40 POAG none 0.40 32 (4) 33 (1) 1.6 T F(3)
80 CAG P-C2 1.00 36 (2) 28 (3) 5.9 T F(3)
30 POAG T3-C1 0.95 17 (3) 18 (4) 2.8 T F(3)
70 CAG P-I-C3 1.00 28 (5) 17 (3) 3.4 T F(3)
80 PEX T3 1.00 26 (1) 44 (1) 9.3 T F(1,3)
40 Pigment none 0.90 30 (2) 29 (1) 4.5 T F(3)
70 PEX none 0.95 30 (4) 42 (1) 18.0 T F(1,3)
80 CAG P-I 0.80 25 (4) 28 (4) 1.0 T F(3)
30 Sec P 0.95 28 (2) 25 (0) 37.1 T-GMS ex F(1,2,3)
50 POAG none 1.00 16 (1) 17 (1) 12.2 T-GMS ex F(1,3)
60 POAG P-A-T2 1.00 20 (3) 34 (0) 1.2 T-GMS ex F(3)
60 Sec P-T1 1.00 24 (2) 50 (1) 14.2 B F(1,3)
60 POAG P-A3-T2 1.00 20 (1) 21 (2) 9.0 B F(1,3)
80 PEX P-T1 0.95 43 (1) 32 (0) 1.3 B F(3)
60 Sec C1 0.60 40 (5) 46 (1) 0.5 Cryo F(3)
60 PEX TA 0.40 27 (2) 28 (1) 5.3 P-GMS ex F(2,3)
60 POAG none 0.75 15 (0) 14 (0) 18.5 GMS ex F(1,2,3)
60 POAG none 0.80 14 (1) 12 (0) 12.2 GMS ex F(1,2,3)
40 POAG none 0.85 17 (0) 18 (2) 21.6 None F(1)
50 POAG T1 1.00 12 (2) 19 (0) 6.7 None F(1)
50 POAG T1 0.95 26 (0) 26 (0) 41.3 None F(1)
40 Pigment B-T1 0.80 20 (2) 24 (2) 6.6 None F(1)
60 POAG P 0.85 28 (5) 14 (0) 46.1 None success
aAge in years when implanted (rounded half to even for de-identification).
bPrevious interventions with number of interventions.
cBaseline IOP (mmHg) on the day before GMS+ implantation (sum of different active ingredients in IOP lowering therapy).
dIOP at the end of the follow-up (mmHg) (sum of different active ingredients in IOP lowering therapy).
eOutcome of GMS+ implant; F, failure (criteria met), for details see Methods.
Abbreviations: Sec secondary glaucoma, P pseudophakic, T trabeculectomy with mitomycin C, I iridectomy, C cyclodestructive intervention, TA trabecular aspiration,
A argon laser trabeculoplasty, B Baerveldt implantation, GMS ex GMS+ explantation, Cryo Cryotherapy.
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The surgical technique of the implantation of the GMS+
had no major operative complications. The GMS+ po-
sition was revised in 3 eyes, when the GMS+ was hardly
visible without gonioscopy.
In our study the implantation of the GMS+ was not ef-
fective in reducing IOP. Most patients required additional
glaucoma surgery within a few months. Melamed et al. [4]
reported surgical success in 79% of their patients, althoughtwo thirds continued with antiglaucoma medications. Their
mean IOP decreased from 27.6 ± 4.7 to 18.2 ± 4.6 mmHg,
compared to our findings, from 26.6 ± 10.1 to 27.2 ±
10.4 mmHg after GMS+ implantation. Figus et al. [5]
achieved a complete success in 5.5% and a qualified success
in 67.3% of the eyes. We cannot explain the remarkable
differences between the results of Melamed and Figus and
our results, despite the following considerations. One rea-
son could be the difference in surgical methods, as we used
Figure 2 Kaplan-Meier survival curve for the outcome of 31
GMS+ implantations.
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close the scleral wound tightly, because the aqueous humor
must be directed to the suprachoroidal space avoiding the
formation of a bleb. The GMS+ we used had a larger
lumen and should have worked provided better flow, in
contrast to the device used by Melamed and Figus. Bend-
ing of the device could occur during insertion and would
be another reason for failure. To account for this problem
Figus performed 50-Mhz and Melamed performed 20-Mhz
controls in all eyes, compared to our 50-Mhz ultrasound
controls in just 39% of the eyes. Study design and length of
follow up appear comparable in all three studies. Patient
characteristics were comparable to Melamed, but Figus
only included patients with failed glaucoma surgery. An-
other reason for the differences between our results and
those of Melamed could be the definition of success and
failure. As shown in Table 1, some of the patients had a
baseline IOP lower than 22 mmHg, so we could not use an
IOP of less than 22 mmHg as the only criteria for success.
To be able to evaluate such patients, our IOP success range
also required that the IOP decrease by 20%, which was not
required by Melamed. In most of these cases, the surgeon
decided to perform an additional glaucoma surgery, be-
cause the individual target IOP was not reached; the target
IOP of most patients was about 12 mmHg. The individual
decision of the surgeon was not controlled by our study
design. Figus defined failure as an IOP >21 mmHg or less
than 33% reduction of IOP on 2 consecutive follow-up
visits after 3 months.
We classified 30 of 31 (97%) GMS+ implantations as
failures. We excluded 7 of 38 patients because of a follow-
up time of less than 6 months. Even if these patientswere counted as successes, 30 of 38 (79%) would have
been failures.
Agnifili et al. [6] examined explanted failed GMS+ and
found connective tissue filling all the inner space and
creating a thick fibrotic capsule surrounding the end of
the device as the possible reason of failure. The GMS+
were explanted 6.8 ± 2.5 months after surgery, which is
comparable to our findings with another surgery within
7.3 ± 7.7 months.
We [3] described the implantation of a silicone tube
from the anterior chamber into the suprachoroidal space
and found a reduced IOP in 70% of the cases after
8 months. In contrast, most of the eyes described here
were unimproved after 8 months. In the reported study
of GMS implants, all eyes had multiple prior glaucoma
surgeries. In the study reported here, many patients
had no prior surgeries and therefore should have been
easier to treat. Suprachoroidal surgery seems to work
better in glaucoma eyes with previously failed glaucoma
surgery [3,5]. The cup-disc ratio in this study was 0.88 ±
0.16, therefore the target IOP of most patients was about
12 mmHg. Because the baseline IOP was 26.6 ± 10.1, a
strong IOP-lowering surgical procedure was necessary in
most cases.
Our surgical technique to implant the GMS+ was com-
parable to the implantation of the silicone tube into the
AC and suprachoroidal space with the use of a scleral flap
[3] and initially recommended by SOLX Inc., but differed
from the surgical technique described by Melamed [4].
They simply incised the sclera and did not prepare a flap.
A third surgical technique was described by the manufac-
turer, SOLX Inc. They recommend cutting the cornea per-
ipherally near the limbus approximately 3.2 mm in length.
They then initiate a Descemet’s plane dissection with a
spatula and dissect along this plane posteriorly with a
Bevel-Down crescent knife to create a pocket in the
supraciliary space. They then insert the GMS+ in the
pocket and within the supraciliary space. They then cut
the Descemet obliquely in the direction of the limbus
and move the GMS+ forward into the anterior chamber
through the Descemet opening. Then the corneal wound is
secured with one or two 10–0 nylon sutures. We preferred
the surgical technique using a small flap to provide a better
view of the choroid. We believe that with both other surgi-
cal techniques it is more likely to damage the choroid, as
the visualization of the choroid is very limited.
The GMS’s design changed over time, for example
channels were made larger. The first GMS had a height
of about 44 μm (this one was used by Melamed [4] and
Figus [5]), the next generation (GMS+) had a height of
68 μm (this one was used in our study), the latest gener-
ation (sGMS+) has a height of 80 μm. With increasing
height, the size of the channels increased. As the likely
mechanism that controls flow in the case of the GMS is
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not the negligible effects from the small luminal dimen-
sions (diameter and length) we should have noticed
equal IOPs and not lower IOPs because of an increased
flow. Nevertheless also the lengths of the channels were
reduced significantly from GMS+ to sGMS+. Another
design change is the orientation of the GMS. The GMS+
should have the narrow part of the shunt in the anterior
chamber and the sGMS+ should have the narrow part of
the shunt in the suprachoroidal space.
The silicone tube we used earlier [3] had a round
lumen with a diameter of 300 μm, which is much larger
than the lumen of all of the GMS’s. Using this silicone
tube from the anterior chamber to the suprachoroidal
space we had a much greater success, compared to our
results with the GMS+.
Theoretically we would prefer a shunt-design that is not
dependant on the shunt lumen, but allows flow from the
anterior chamber to the suprachoroidal space through the
inner lumen, and also at the outside of the shunt, providing
even more flow into the suprachoroidal space.
The CyPass implant (Transcend Medical, Menlo Park,
California, USA) is a new microsurgically implantable de-
vice composed of biocompatible, non-degradable, poly-
imide material. The implant is inserted ab interno through
a 1.5 mm clear corneal incision under intraoperative
gonioscopy into the supracilliary space. It should create a
controlled cyclodialysis and a permanent internal drainage
into the suprachoroidal space. Initial clinical experience
showed a low rate of surgical complications with concomi-
tant decreases in IOP and/or glaucoma medications [7].
Probably the success rate of the CyPass device could be
related to the cyclodialysis and using more than one de-
vice in the same eye could be useful. Obviously CyPass
implant or other ab interno devices will have a lower
rate of intraoperative complications and could substitute
the GMS.
The change in color of the choroid, shown at explant-
ation of the GMS+ (Figure 1C) could be a sign of filtration
or a sign of chronic inflammation with reduced blood flow
through the choroid.
Signs of chronic inflammation after trabeculectomy is a
rare incident [8], and probably related to the prevalence of
anterior uveitis in the population. We found in four of the
GMS+ implanted eyes (13%) signs of chronic inflammation
or new developed rubeosis iridis. The purity of the gold for
the GMS+ is stated as 99.95% and a case report describing
a foreign body made of gold with 8.25% copper did not ir-
ritate the eye for 9 years [9], so the reason for the chronic
inflammation and new developed rubeosis iridis remains
unknown and has to be further investigated.
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